Inside the research
Elevance Health, Inc.
ELV Research profile · latest available data
Price overview
$396.09
▼ -2.16 (-0.5%)
| 52w hi | $424.94 |
|---|---|
| 52w lo | $276.68 |
| Vol | 1.22M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.31
| Short | +0.33 |
|---|---|
| Medium | +0.41 |
| Long | +0.07 |
computed 2026-09-27
Key fundamentals
Elevance Health, Inc.
Healthcare · Healthcare Plans
| Market cap | $85.90B |
|---|---|
| Enterprise value | $79.57B |
| Trailing P/E | 17.51x |
| Forward P/E | 13.41x |
| EV / EBITDA | 9.56x |
| P / S (ttm) | 0.43x |
| Profit margin | 2.5% |
| Return on equity | 11.1% |
| Revenue growth | +1.4% |
| Earnings growth | -13.1% |
| Debt / equity | 68.95 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.12 | |
| Sector | +0.08 | |
| Technical | +0.25 | |
| Earnings | +0.00 | |
| Sentiment | -0.00 |
macro × 1.00 · 2026-09-27
Business overview
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
Risk Metrics
| Beta vs SPX | 0.24 |
|---|---|
| Corr SPX | 0.11 |
| Annual vol | 36.0% |
| Annual ret | -8.9% |
| Sharpe | -0.25 |
| Max DD | -48.6% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $388.95 |
|---|---|
| High / Low | $474.00 / $331.00 |
| Median | $391.00 |
| Analysts | 21 |
| Strong Buy | 3 | |
|---|---|---|
| Buy | 11 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-29 | B of A Securities | → Buy |
| 2026-04-28 | JP Morgan | → Overweight |
| 2026-04-24 | Guggenheim | → Buy |
| 2026-04-24 | Barclays | → Overweight |
| 2026-04-23 | Evercore ISI Group | → In-Line |
| 2026-04-23 | Baird | → Neutral |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-15 | Earnings Release, Exhibits | read |
| 2026-06-10 | Reg FD Disclosure | read |
| 2026-05-13 | Shareholder Vote | read |
| 2026-04-22 | Earnings Release, Exhibits | read |
| 2026-03-10 | Reg FD Disclosure | read |
| 2026-03-02 | Other Material Event | read |
| 2026-02-26 | Officer / Director Change, Reg FD Disclosure | read |
| 2026-01-28 | Earnings Release, Exhibits | read |
| 2025-12-10 | Officer / Director Change | read |
| 2025-11-10 | Reg FD Disclosure | read |
| 2025-10-21 | Earnings Release, Exhibits | read |
| 2025-09-15 | Other Material Event, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | PERU RAMIRO G | Buy | 1.00K | $366.05K | |
| 2026-07-17 | BOUDREAUX GAIL | President and CEO | Buy | 680 | $249.16K |
| 2026-07-17 | BOUDREAUX GAIL | President and CEO | Buy | 2.04K | $753.07K |
| 2026-06-12 | Penczek Ronald W | CAO & Controller | Sell | 369 | $148.77K |
| 2026-06-11 | Dixon Robert L JR | Sell | 151 | $60.67K | |
| 2026-05-19 | Penczek Ronald W | CAO & Controller | Option exercise | 654 | $177.41K |
| 2026-05-19 | Penczek Ronald W | CAO & Controller | Sell | 1.53K | $617.19K |
| 2026-05-19 | Penczek Ronald W | CAO & Controller | Option exercise | 877 | $273.17K |
| 2026-05-13 | SCHULMAN AMY W | Grant | 563 | — | |
| 2026-05-13 | Schneider Ryan M. | Grant | 563 | — |
Flow & Concentration
| Insider 180d net | $541.65K |
|---|---|
| Insider buys / sells | 3 / 3 |
| Insider bias | Neutral |
| 13F holders | 1 |
| Top-5 share | 100.0% |
| HHI | 10,000 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| BlackRock Inc | $11.22B | 20.70M |
As of 2024-06-30
Connections
Subsidiarys: Carelon Global Solutions (BPO/Shared Services subsidiary)
Dividends
| Yield (TTM) | 0.87% |
|---|---|
| $ / share (TTM) | $3.43 |
| 5y CAGR | +12.5% |
Annual dividend per share
| 2021 | $4.52 |
|---|---|
| 2022 | $5.12 |
| 2023 | $5.92 |
| 2024 | $6.52 |
| 2025 | $6.84 |
| 2026 | $1.72 |
SEC Filings
The Long Run
FY 2009–2025 · 16 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $177.01B | +7.3% | |
| Operating income | $8.50B | +4.9% | |
| Net income | $5.66B | +1.2% | |
| Cash from ops | $8.06B | +4.2% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $400.00 | $405.13 | $394.69 | $396.09 | 1.22M |
| Sep 24 | $397.00 | $400.97 | $394.31 | $398.25 | 1.17M |
| Sep 23 | $400.84 | $404.39 | $396.37 | $398.56 | 1.21M |
| Sep 22 | $412.07 | $412.75 | $401.38 | $402.43 | 1.12M |
| Sep 21 | $410.31 | $411.48 | $406.20 | $409.31 | 934.00K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →